Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field of science called Intersystems Biology, has announced that it has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.
Latham & Watkins LLP represents Senda Biosciences in the transaction. The strategic collaboration was led by partner Judith Hasko, with associates Jekkie Kim and Seth Appiah-Opoku. Corporate aspects of the transaction were led by partner Peter Handrinos, with associate Samuel Niles. Advice was also provided on tax matters by partner Kirt Switzer, with associate Derek Berry; and on regulatory matters by partner Ben Haas.